The Drug Controller General of India (DCGI) will address a press conference on Sunday (January 3) at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines.
The Drug Controller General of India (DCGI) will address a press conference today at 11 am and it is being expected that the drug controller watchdog may announce the approval of emergency use of two vaccines. The development comes after the government panels recommended — Oxford-AstraZeneca Covishield and Bharat Biotech's Covaxin — for emergency use.
An expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.
An expert panel on Saturday recommended granting permission for restricted emergency use authorisation for Bharat Biotech's indigenously developed COVID-19 vaccine — Covaxin.
The analysis of the additional data and information submitted by Serum Institute of India (SII) and Bharat Biotech is still being conducted by regulator Central Drug Standard Control Organisation's (CDSCO) Subject Expert Committee and their next meeting will be held on January 1.
Covaxin, a vaccine candidate being developed by Bharat Biotech for COVID-19, can offer protection against mutations of coronavirus, Chairman andManaging Director of the city-based vaccine maker Krishna Ella said on Tuesday.
AIIMS has invited volunteers for the Phase III clinical trial of the indigenously developed COVID-19 vaccine candidate Covaxin for which it is one of the sites.
The All India Institute Of Medical Sciences (AIIMS) has invited applications for volunteers, who want to take part in the COVAXIN Phase-3 trial, which was indigenously developed by Bharat Biotech.
Hyderabad-based Bharat Biotech, which is developing the country's indigenous coronavirus vaccine in collaboration with the Indian Council of Medical Research, on Wednesday again applied to the Drug Controller General of India for the emergency use authorisation.
Covaxin, being developed in collaboration with the Indian Council of Medical Research and the National Institute of Virology, is now undergoing phase-3 trials.
Bharat Biotech is developing Indian own vaccine for coronavirus called Covaxin. Its chairman was speaking in a virtual session on 'Sero surveillance significance in immunogenicity and safety in pre and post vaccination era' organised by industry body CII.
Bharat Biotech on Tuesday announced successful recruitment of 13,000 volunteers and continued progress towards achieving the goal of 26,000 participants for Phase-3 clinical trial of first Make in India vaccine candidate, Covaxin across multiple sites in India.
United Nations Children's Fund (UNICEF) could potentially transport up to 850 tonnes of Covid-19 vaccines per month in 2021, should such quantities become available, according to a new assessment published on Friday.
The rollout of Covid-19 vaccine by Bharat Biotech for the general public may get delayed as the All India Institute of Medical Sciences (AIIMS), where its Phase-III human clinical trial is underway, is struggling to find takers of the trial shots, the official heading the project told IANS.
Bharat Biotech's Covaxin was "well-tolerated" in all dose groups, the company said Wednesday as it released interim findings of phase 1 trials.
Covaxin, the COVID vaccine candidate by Hyderabad-based vaccine manufacturer Bharat Biotech Limited, being developed in collaboration with the Indian Council of Medical Research (ICMR), is likely to be available for use of the general public by the end of February 2021, Dr Sanjay Roy, principal investigator (PI) heading its clinical trial at AIIMS, told IANS on Tuesday.
After vaccine major Serum Institute of India (SII), Bharat Biotech on Monday applied to the Drugs Controller General of India (DCGI) for emergency use authorisation for its indigenously developed coronavirus vaccine called Covaxin.
The phase-3 human clinical trial of India's own vaccine for coronavirus, Covaxin will begin at the SRM Medical College Hospital and Research Centre in Chennai.
Pfizer India has become the first pharmaceutical firm to approach the Drugs Controller General of India (DCGI) seeking an emergency use authorisation for its Covid-19 vaccine in the country.
Anil Vij had offered to be the first volunteer in the phase three trials for Covaxin, an indigenous potential vaccine against COVID-19 being developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).
Top News
Latest News
